SNDX FY 2021 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$140M+9109.6% YoY

Gross Profit

$140M100.0% margin

Operating Income

$26M18.8% margin

Net Income

$25M17.8% margin

EPS (Diluted)

$0.48

Cash Flow

Operating Cash Flow

$29M

Free Cash Flow

$29M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$450M

Total Liabilities

$41M

Stockholders' Equity

$408M

Cash & Equivalents

$222M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$140M	$2M	+9109.6%
Gross Profit	$140M	$2M	+9109.6%
Operating Income	$26M	-$71M	+136.7%
Net Income	$25M	-$73M	+134.1%